ArticleCardiovascular therapeutics2026
A Novel Intracardiac Echocardiography-Guided Approach for Vein of Marshall Ethanol Infusion in Persistent Atrial Fibrillation Ablation.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.Clinical cardiology · 2026Review
- A Novel Intracardiac Echocardiography-Guided Approach for Vein of Marshall Ethanol Infusion in Persistent Atrial Fibrillation Ablation.Cardiovascular therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe vein of Marshall (VOM) ethanol infusion is an adjunctive strategy for persistent atrial fibrillation (AF) ablation, traditionally guided by VOM venography. However, venography does not allow real-time evaluation of ethanol distribution and carries procedural risks. Intracardiac echocardiography (ICE) provides high-resolution visualization for precise guidance but remains understudied clinically. This study was aimed at evaluating the feasibility, efficacy, and safety of a novel ICE-guided VOM ethanol infusion.
methodsA retrospective, matched cohort study was conducted including 126 patients (42 ICE-guided, 84 venography-guided) undergoing de novo radiofrequency (RF) catheter ablation for persistent AF. Propensity score matching (1:2) balanced the groups' baseline characteristics. Procedural endpoints included ethanol-induced low-voltage area (LVA), procedural efficiency (procedure duration and radiation exposure), complications, and 12-month AF/atrial tachycardia (AT) recurrence. ICE-guided procedures utilized real-time monitoring of ethanol-induced tissue changes, whereas venography relied on contrast extravasation.
resultsICE guidance produced significantly larger ethanol-induced LVAs, shorter total procedure times, reduced fluoroscopy times, shorter VOM ethanol infusion times, shorter mitral isthmus (MI) ablation times, and lower radiation exposure (all p < 0.05). Major complications were rare and similar between groups (p = 0.719). At 12 months, freedom from AF/AT recurrence was comparable between groups (log-rank test, p = 0.66).
conclusionsICE-guided VOM ethanol infusion enhances procedural precision, reduces radiation exposure, and achieves more extensive substrate modification compared with venography. Although clinical recurrence rates were similar, ICE improves workflow efficiency and improves safety by avoiding distal VOM cannulation. These findings support ICE as a transformative tool for optimizing VOM ethanol ablation. Limitations include the nonrandomized design and small sample size, which warrant further validation in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.